Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Neurocrine Bio. (NBIX) PT Bumped to $66 at Baird on NBI-98854 Phase 3 Success
October 8, 2015 1:44 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and bumped his price target on Neurocrine Bio. (NASDAQ: NBIX) to $66.00 (from $64.00) saying the Phase 3 success gives them confidence in the outlook.
Skorney commented, "NBI-98854's success in Phase 3 makes the path towards approval... More
Neurocrine Bio. (NBIX) Bullish Stance Reiterated at Cowen
October 8, 2015 12:46 PM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and $55 price target on Neurocrine Bio. (NASDAQ: NBIX) after the company announced strongly positive Phase III data for '854 in Tardive Dyskinesia (TD). '854 (80 mg QD) reduced the AIMS score by 3.1 points vs. placebo (p... More
Neurocrine Bio (NBIX) PT Raised to $96 at Piper Jaffray
October 8, 2015 10:52 AM EDTPiper Jaffray analyst Charles C. Duncan reiterated an Overweight rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $86.00).
Duncan commented, "Today Neurocrine announced positive Phase III results on '854 in Tardive Dyskinesia patients with an underlying psychiatric disorder. Although... More
Pre-Open Stock Movers 10/08: (JMG) (BMR) (EMC) Higher; (CSII) (ORIG) (SHAK) Lower (more...)
October 8, 2015 9:28 AM EDTJournal Media Group, Inc. (NYSE: JMG) 42% HIGHER; Gannett (NYSE:... More
Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive Dyskinesia
October 8, 2015 6:34 AM EDTNeurocrine Biosciences (NASDAQ: NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying... More
